Successful Treatment of Aggressive Post Transplant Lymphoproliferative Disorder using Rituximab
- 1 January 2000
- journal article
- case report
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 39 (3-4) , 411-419
- https://doi.org/10.3109/10428190009065842
Abstract
A 52 year -old female developed a histologically aggressive, Epstein-Barr virus positive, lymphoproliferative disorder involving the brain and liver 4 months following a combined kidney/pancreas transplant. Following a brief trial of reduced immunosuppression, she was treated with rituximab. Despite subsequent re-intensification of immunosuppression, the lesions showed continued regression with almost complete disappearance by 5 months. Rituximab appears to be a safe, effective treatment for post transplant lymphoproliferative disorder.Keywords
This publication has 9 references indexed in Scilit:
- Epstein-Barr virus and lymphoproliferative diseaseCurrent Opinion in Hematology, 1999
- INTERFERON-?? TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1Transplantation, 1998
- Anti–B-Cell Monoclonal Antibody Treatment of Severe Posttransplant B-Lymphoproliferative Disorder: Prognostic Factors and Long-Term OutcomeBlood, 1998
- BCL-6 Gene Mutations in Posttransplantation Lymphoproliferative Disorders Predict Response to Therapy and Clinical OutcomeBlood, 1998
- The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevantCancer, 1998
- AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER CELL THERAPY OF EPSTEIN-BARR VIRUS-POSITIVE AND -NEGATIVE LYMPHOPROLIFERATIVE DISORDERS ARISING IN ORGAN TRANSPLANT RECIPIENTS1Transplantation, 1997
- Cancer Arising After Pancreas and/or Kidney Transplantation in a Series of 99 Diabetic PatientsDiabetes Care, 1997
- Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disordersBlood, 1995
- Monoclonality of Lymphoproliferative Lesions in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1984